晚期结直肠癌精准分子靶向治疗研究进展

Research progress in precise molecular targeted therapy for advanced colorectal cancer

结直肠癌是常见的消化系统恶性肿瘤,具有起病隐匿、复发转移风险高、预后差等特点。近年来,针对RAS、BRAF、MMR/MSI、HER2、MET、NTRK、POLE/POLD1等不同分子分型结直肠癌的靶向治疗相关临床研究均取得了一定的成果。此外,结直肠癌分子靶向治疗与其他疗法联合应用的探索也在不断进行。阐明结直肠癌分子靶向治疗作用机制及临床应用进展,可为结直肠癌患者临床治疗方案的制定提供更可靠的依据。

Colorectal cancer is a common malignant tumor of the digestive system,with the characteristics of insidious onset,high risk of recurrence and metastasis,and poor prognosis.In recent years,clinical researches related to targeted therapy for colorectal cancer of different molecular subtypes such as RAS,BRAF,MMR/MSI,HER2,MET,NTRK,and POLE/POLD1 have all achieved certain results.Besides,the exploration of the combined application of molecular targeted therapy for colorectal cancer and other therapies is also continuously carried out.Clarifying the mechanism of action and clinical application progress of molecular targeted therapy for colorectal cancer can provide a more reliable basis for formulating clinical treatment plans for colorectal cancer patients.